Clinical Features of Primary Pulmonary Artery Sarcoma: A Systematic Review and Pooled Analysis.

Objectives: Primary pulmonary artery sarcoma (PPAS) is a rare disease with unclear clinical manifestations. Advances in imaging devices have improved diagnostic capabilities, potentially affecting clinical characteristics and overall survival (OS); however, details remain unclear. This study conducted a pooled analysis of case reports and series to analyse the clinical characteristics and OS of PPAS in the era of advanced medical devices.

Employing a low-code machine learning approach to predict in-hospital mortality and length of stay in patients with community-acquired pneumonia.

Community-acquired pneumonia (CAP) is associated with high mortality rates and often results in prolonged hospital stays. The potential of machine learning to enhance prediction accuracy in this context is significant, yet clinicians often lack the programming skills required for effective data mining. This study aimed to assess the effectiveness of a low-code approach for assisting clinicians with data mining for mortality and length of stay (LOS) prediction in patients with CAP.

Effectiveness of upfront triple oral combination therapy with additional pirfenidone in a patient with severe pulmonary hypertension associated with lung diseases.

Diagnosis and treatment of pulmonary hypertension (PH) in patients with lung diseases (PH-LD) remain unestablished and pose significant challenges. In this report, we present a case of a 77-year-old patient with an indeterminate for usual interstitial pneumonia pattern along with chronic obstructive pulmonary disease, who developed groups 1 and 3 PH. Following diagnosis, upfront triple oral combination therapy (UTOCT) with macitentan, sildenafil, and selexipag was initiated.

Effective treatment of exon 14 skipping mutation-positive non-small cell lung cancer using capmatinib following serious maculopapular rash caused by two MET inhibitors: a case report.

Background: Multi-gene panel testing and advancements in molecular targeted therapy have improved the overall survival of patients with driver mutation-positive non-small cell lung cancer (NSCLC). Mesenchymal-epithelial transition factor () exon 14 skipping mutation-positive NSCLC, which remains untreated with MET inhibitors, shows a poorer prognosis than do cases of NSCLC without mutations. However, serious treatment-related adverse events (TRAEs) act as substantial treatment barriers.